Skip to main content
EVMNEvommune—

Evommune (EVMN) Q2 2026 earnings — TrendMatrix coverage

MISS · WIDER LOSS-32.8% vs estimateEPS -$0.89 vs -$0.67 est

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Adjusted EPS
-$0.89
Estimate
-$0.67
Surprise
-32.8%

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q2 2026

How the report landed

Evommune (EVMN) reported a wider loss than forecast — adjusted EPS of -$0.89 against the -$0.67 estimate (a 32.8% shortfall).

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › EVMN › Earnings › Q2 2026 earnings